## Marcello Deraco

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9359420/marcello-deraco-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16<br/>papers512<br/>citations9<br/>h-index20<br/>g-index20<br/>ext. papers604<br/>ext. citations2.1<br/>avg, IF3.16<br/>L-index

#	Paper	IF	Citations
16	Fertility preservation in women with peritoneal surface malignancies: A case series. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 2948-2951	3.6	1
15	The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 2888-2892	3.6	6
14	Diagnostic and therapeutic algorithm for colorectal peritoneal metastases. A consensus of the peritoneal surface malignancies onco-team of the Italian society of surgical oncology. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 164-171	3.6	1
13	Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). European Journal of Surgical Oncology, 2021, 47, 1132-1139	3.6	6
12	Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 98-106	3.1	15
11	Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 1184-1192	3.1	24
10	Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 404-413	3.1	40
9	Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers. <i>Surgical Oncology Clinics of North America</i> , <b>2018</b> , 27, 507-517	2.7	15
8	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. <i>Gynecologic Oncology</i> , <b>2011</b> , 122, 215-20	4.9	111
7	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Peritoneal Mesothelioma and HIV Infection. <i>Tumori</i> , <b>2010</b> , 96, 340-344	1.7	2
6	Experience with peritoneal mesothelioma at the Milan National Cancer Institute. <i>World Journal of Gastrointestinal Oncology</i> , <b>2010</b> , 2, 76-84	3.4	21
5	Consensus statement on peritoneal mesothelioma. <i>Journal of Surgical Oncology</i> , <b>2008</b> , 98, 268-72	2.8	72
4	Advances in clinical research and management of diffuse peritoneal mesothelioma. <i>Recent Results in Cancer Research</i> , <b>2007</b> , 169, 137-55	1.5	3
3	Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. <i>Annals of Surgical Oncology</i> , <b>2006</b> , 13, 229-37	3.1	124
2	Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center. <i>In Vivo</i> , <b>2006</b> , 20, 773-6	2.3	8
1	Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study. <i>Tumori</i> , <b>2001</b> , 87, 120-126	1.7	63